{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Joshi M"],"funding":["Celgene","MAK-D discloses consultancy for Daiichi Sankyo Company and Pharmacyclics","Institutional research support","Research support","AbbVie"],"journal":["Blood cancer journal"],"pagination":["49"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7933161"],"repository":["biostudies-literature"],"pubmed_title":["Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation."],"pmcid":["PMC7933161"],"pubmed_authors":["Joshi M","Patnaik M","Alkhateeb HB","Gangat N","Al-Kali A","Shah MV","Elliot M","McCullough K","Kharfan-Dabaja MA","Begna K","Hogan WJ","Sproat L","Tefferi A","Cook J","Murthy HS","Foran JM","Nanaa A","Pardanani A","Litzow MR","Palmer J"],"additional_accession":[]},"is_claimable":false,"name":"Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.","description":null,"dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-22T08:22:26.47Z","creation":"2025-04-05T22:30:33.376Z"},"accession":"S-EPMC7933161","cross_references":{"pubmed":["33664234"],"doi":["10.1038/s41408-021-00437-z"]}}